Is Zoetis (ZTS) a risky stock?
As of July 21, 2026, Clavix grades Zoetis (ZTS) B- for risk, a composite score of 67 out of 100 on an A+ to F scale, which puts ZTS in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind ZTS's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how ZTS scores on each, as of July 21, 2026.
What's moving ZTS's risk right now
Company-specific signals Clavix flags behind ZTS's current grade, drawn from recent news and filings as of July 21, 2026.
A class action lawsuit alleging securities fraud is moving forward against Zoetis, with investors invited to take the lead role before the deadline. The case creates legal costs and management distraction that could pressure the stock in the near term.
Zoetis has launched Lenivia, a new long-acting injection for osteoarthritis pain in dogs, in Canada and the European Union. The rollout adds a major therapy to its companion animal portfolio across two large international markets, which could lift segment revenue.
Zoetis launched Lenivia, a long-acting injection for osteoarthritis pain in dogs, across Canada and the EU. The move broadens the company's pain management lineup in companion animals and could support future revenue growth.
What a B- grade means
On the Clavix A+ to F scale, ZTS's composite of 67 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell ZTS or any security. Grades are risk indicators, not predictions of return. Data may be delayed.